/ /

  • linkedin
  • Increase Font
  • Sharebar

    2015 ARVO finds connections in innovative drug delivery, therapies

    Cutting-edge progress also continues in retina, cornea, dry eye, gene-based science

     

    Since ARVO always highlights cutting-edge scientific progress, it was not surprising to see a number of presentations that described the latest in progress toward genetically based therapies. One of these reports combined gene-editing CRISPR technology and genetically modified, induced pluripotent stem cells to generate 3-D retina reporter cell lines for the study of photoreceptors (Wahlin KJ. IOVS. 2015;56:ARVO E-Abstract 3596).

    Several studies focused on utilizing gene therapy to target the oxidative stress that accompanies a number of retinal diseases. By utilizing a mouse model of retinal pigment epithelium oxidative stress, it was demonstrated that delivery of genes for antioxidant enzymes can be used as a tool to reverse oxidative stress (Biswal MR. IOVS. 2015;56:ARVO E-Abstract 3189).

    In contrast, another study proposed targeting of transcription factors that regulate hundreds of genes that combat oxidative stress would be more effective than the delivery of antioxidant enzymes (Xiong W IOVS 2015; 56: ARVO E-Abstract 3188).

     

    In the blink of an eye

    Two presentations used continuous monitoring technology to analyze blink behavior under natural conditions (Lane. IOVS. 2015;56:ARVO E-Abstract 4447; Harmeling. IOVS. 2015;56:ARVO E-Abstract 4486). These studies continue to advance clinicians’ understanding of compensatory mechanisms in ocular surface disease.

     

     

     

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results